EXCLUSIVE: Kevin O'Leary On Why Cannabis Industry Attracts 'Zero' Institutional Dollars

Zinger Key Points
  • The cannabis industry needs to convince President Joe Biden to remove cannabis from the Schedule 1 list, O'Leary says, so the industry can be bifurcated into FDA-approved medicine and recreational sales.
  • “You’ve got a lot of tension in the space that should have been resolved early on,” he says. “Recreational cannabis is great, but it’s a nothing burger compared to what it would be if it were medicine.”

While “Shark Tank” judge Kevin O’Leary views legal psychedelics as a once-in-a-lifetime investment opportunity, his take on cannabis is 180 degrees away.

“There isn’t a dime of institutional money here, at the sovereign level,” O’Leary told Benzinga founder and CEO Jason Raznick in a keynote discussion Tuesday at the inaugural Benzinga Psychedelics Capital Conference. “Zero. The industry, in my view, screwed itself.”

Why? The federal status of cannabis as a Schedule 1 drug.

That distinction makes cannabis difficult for institutional investors, said O’Leary, who is the chairman of O’Shares ETFs, among other pursuits.

O’Leary Says ‘Soul-Searching’ Needed In Cannabis: Transporting cannabis across state lines could trigger RICO statutes, O’Leary said.

“I don’t want to be the test case for that theory.”

Ahead of the two-day Benzinga Cannabis Capital Conference, O’Leary suggested the industry “do some soul-searching and say, ‘how do we fix this?’”

The cannabis industry needs to convince President Joe Biden to remove cannabis from the Schedule 1 list, he said, so the industry can be bifurcated into FDA-approved medicine and recreational sales.

“You’ve got a lot of tension in the space that should have been resolved early on,” he said. “Recreational cannabis is great, but it’s a nothing burger compared to what it would be if it were medicine.”

Why Canadian Cannabis Margins Are ‘Getting Crushed’: O’Leary, who was born in Montreal, gave a thumbs-down Tuesday to the Canadian cannabis space from an investment standpoint.

Referring to the province of Ontario, he said: “That business sucks. They don’t allow them to brand anything.”

The price-to-earnings ratios of Canadian cannabis stocks “have been crushed,” O’Leary said.

“There’s no differentiation. [Canadian cannabis companies] are selling it as a commodity and margins are getting crushed.”

"Shark Tank" judge Kevin O'Leary speaks Tuesday at the Benzinga Psychedelics Capital Conference in Miami Beach, Florida. Photo by Dez Smith. 

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: CannabisNewsPsychedelicsEventsExclusivesMarketsCCCCCC22Jason RaznickKevin O'LearyPCCPCC22Shark Tank
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

The Top Cannabis Event In New Jersey

Join the Benzinga Cannabis Market Spotlight in New Jersey on June 17th! Grow your business, raise money and capitalize on the booming NJ recreational market. Don’t miss this must-attend event in New Brunswick. Secure your tickets now. Very few spots are left. Use the code "JAVIER20" for 20% off!


Loading...